A human‐based case study, conducted in three Mexican NAFLD patients, also showed a significant reduction in ALT blood level concomitant to ameliorating dyslipidemia (Ferreira‐Hermosillo et al., 2010). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.